Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in ...

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, ...

Cipla's US sales for the June quarter stood at $226 million, which was higher than the CNBC-TV18 poll estimate, that ranged ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Total Income from operations rose to Rs 6,957 crore for the June quarter as compared with Rs 6,694 crore in the year-ago ...

Mumbai-based pharmaceutical major Cipla has reported its financial results for the April-June period, with a ...

Cipla Q1 FY26 Results Preview, Pharma Stock Price vs Nifty 50: Cipla shares are trading with cautious gains with investors ...

Cipla , India's third-largest drugmaker by sales, reported a better-than-expected quarterly profit on Friday, driven by higher domestic demand for its generic respiratory drugs.